IL15 and cancer: Our contribution to cancer immunotherapy was the discovery of a methodology for expanding the bispecific antibody platform by crosslinking an anti-CD16 single chain variable fragment (scFv) and an scFv recognizing cancer antigens with the cytokine interleukin 15 (IL-15) [10].